US Patent

US9763953 — Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

Method of Use · Assigned to Neurodyn Life Sciences Inc · Expires 2026-12-01 · 1y remaining

Vulnerability score 93/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds with improved blood-brain barrier permeability derived from amaryllidaceae alkaloids for treating diseases with cognitive impairment.

USPTO Abstract

The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g., galantamine, narwedine and lycoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as “pro-drugs”, in the sense that after reaching their target regions in the body they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this invention may be used as medicaments.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-713 benzgalantamine-gluconate
U-713 benzgalantamine-gluconate
U-713 benzgalantamine-gluconate

Patent Metadata

Patent number
US9763953
Jurisdiction
US
Classification
Method of Use
Expires
2026-12-01
Drug substance claim
No
Drug product claim
No
Assignee
Neurodyn Life Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.